One-year Clinical Outcomes of Biodegradable Polymer Coated Everolimus-eluting Coronary Stent: Results from a Prospective, Open-label, Non-randomized Study

Purpose Everoshine everolimus-eluting coronary stent (EECS) is a newer-generation, ultrathin (65 µm) biodegradable polymer-coated stent. This study aimed to evaluate the safety and efficacy of the Everoshine EECS in patients with coronary artery disease (CAD). Methods This was a single-center, single-arm, prospective study, which enrolled patients aged ≥18 years who had at least one native coronary artery lesion and were eligible for Everoshine EECS implantation. The primary endpoint was major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI), and target lesion revascularization, assessed at the 30-day follow-up. Results A total of 193 patients were enrolled (mean age 57.8 ± 11.0 years; 142 [73.6%] male). Of these, 92 (47.7%) patients had ST-segment elevation MI (STEMI) and 39 (20.2%) had non-STEMI. A total of 267 stents were deployed, with a mean diameter of 2.9 ± 0.4 mm and a mean length of 27.0 ± 9.9 mm. At 30 days, 3 (1.6%) patients experienced MACE, and 2 (1.0%) patients experienced stent thrombosis (ST). Cumulative MACE was observed in 5 (2.6%) patients at one year. Conclusion One-year clinical outcomes demonstrated satisfactory efficacy and safety of the novel biodegradable polymer-coated Everoshine EECS in patients with CAD attributable to native coronary artery stenosis.